The effect of long-term treatment with atropine, a muscarinic antagonist, known to cause up-regulation of receptor numbers, was examined on the muscarinic-receptor-mediated stimulation of phosphoinositide breakdown in the rat cerebral cortex and hippocampus. Although the numbers of both Ml muscarinic receptors, as measured by [3H]pirenzepine binding, and Ml and M2 receptors increased in both brain regions, the maximal breakdown of myo-[3H]inositol-labelled phosphoinositides was unaltered in the presence of carbachol at a saturating concentration (102 M). In fact the efficacy of carbachol was decreased in slices from atropine-treated cerebral cortex [EC50 (concentration producing half-maximal effect) = 93 /M] as compared with the saline-treated control (EC50 = 23 uM) (P < 0.005). Similarly the EC50 value (23 /M) in hippocampal slices from saline-treated rats increased in atropine-treated rats to 126,M (P < 0.005). This lowered efficacy of muscarinic stimulation could not be explained in terms of residual atropine in the tissue from treated rats. The noradrenaline-or serotonin (5-hydroxytryptamine)-stimulated breakdown or the K+ potentiation of the muscarinic-receptor-stimulated breakdown of [3H] 
INTRODUCTION
In rat cerebral-cortical slices and slices from the rat hippocampus, muscarinic cholinergic agonists stimulate the hydrolysis of inositol-containing lipids (Hokin & Hokin, 1 953; Michell, 1975; Gonzales & Crews, 1984; Janowsky et al., 1984) and thus give rise to at least two second messengers: inositol 1,4,5-trisphosphate and diacylglycerol (Michell et al., 1981; Michell, 1983; Nishizuka, 1984; Hokin, 1985; Berridge, 1986) . The muscarinic stimulation can be blocked by the specific muscarinic antagonist atropine (cf. Taylor, 1980) . Long-term treatment of rats with atropine has been shown to lead to the development of physiological, behavioural and pharmacological supersensitivity, presumably as a compensation for decreased muscarinic cholinergic transmission caused by long-term blockade of the receptors (Herman & Slominska-Zurek, 1979 ; Takeyasu et al., 1979) . The chronic atropine treatment was found to cause an up-regulation of muscarinicreceptor numbers in both cerebral cortex and hippocampus (Ben-Barak -& Dudai, 1980; Wise et al., 1980; Westlind et al., 1981) . Less is known about the involvement of the different muscarinic-receptor-coupled second-messenger systems (regulation of cyclic AMP and cyclic GMP synthesis, alterations in K+ conductance and phosphoinositide turnover) in the adaptive processes of supersensitivity, subsensitivity and tolerance. In the rat striatum, however, it was demonstrated that chronic inhibition of acetylcholinesterase activity and subsequent down-regulation of the number of muscarinic receptors was parallelled by a decreased ability for muscarinic agonists to inhibit the dopamine-sensitive adenylate cyclase (Olianas et al., 1984) .
In the present study we investigated whether chronic blockade -of muscarinic receptors in vivo by atropine (which causes up-regulation of receptor numbers) also changes the ability of the cholinergic agonist carbachol to stimulate phosphoinositide turnover via muscarinic receptors in the rat cerebral cortex and rat hippocampus.
MATERIALS AND METHODS Materials
Carbamylcholine chloride, (± )-arterenol hydrochloride, L-phenylephrine hydrochloride, 5-hydroxytryptamine (serotonin) hydrochloride and myo-inositol were purchased from Sigma Chemical Co., St. Louis, MO, U.S.A. Atropine sulphate was from Merck A.G., Dortmund, Germany, and myo-[2-3H]inositol (17.1 Ci/mmol), L-quinuclidinyl [benzilic-4,4-3H(n)]benzilate ([3H]QNB; 33.2 Ci/mmol) and [N-methyl-3H] pirenzepine ([3H] Pz; 76.0 Ci/mmol) were from du 1,4,5-trisphosphate (potassium salt; 1.0 Ci/mmol) were from Amersham International, Amersham, Bucks., U.K. Dowex 1-X8 (100-200 mesh) and AG 1-X8 (200-400 mesh) ion-exchange resins were purchased from Bio-Rad Laboratories. St. Albans, Herts., U.K. All reagents used were of analytical grade.
Atropine treatment
Male Sprague-Dawley rats (160-180 g) were injected subcutaneously in the back once daily between 13:00 and 15: 00 h with atropine sulphate (20 mg/kg) in phosphate-buffered (100 mm, pH 7.4) saline or with vehicle alone for 14 days. The animals were decapitated 45 h after the last injection, and the brains were rapidly removed, dissected on ice, and brain regions immediately used for phosphoinositide-turnover determinations or frozen on solid CO2 and stored at -70°C for measurements of receptor concentration by binding of 3H-labelled antagonists.
Binding studies (a) Tissue preparation. Rat cerebral cortices or hippocampi were thawed and homogenized by using a loosefitting glass/Teflon homogenizer at 695 rev./min by 15 up-and-down strokes to yield a 5 % (w/v) homogenate in ice-cold Krebs-Ringer buffer (KRB-A) containing 137 mM-NaCl, 2.7 mM-KCl, 1.8 rM-CaCl2, 1 mM-MgCl2, 5 mM-Hepes, and adjusted to pH 7.4 with NaOH.
The homogenate was subsequently sonicated with five 1 s pulses at setting 5 in a Branson cell-disruptor B15 sonifier and then centrifuged at 64000 g for 30 min in a Beckman L-550 ultracentrifuge.
The supernatant was discarded and the pellet was rinsed twice with 5 ml of ice-cold KRB-A buffer and resuspended in the initial volume as described above.
Homogenates were diluted to the appropriate protein concentration (0.15-0.25mg/ml) The incubations were initiated by addition of membranes to temperature-equilibrated tubes containing ligands. The incubations were terminated by addition of ice-cold KRB-A buffer (10 ml) to the tubes, and the contents were passed rapidly by suction through a glassfibre filter (Whatman GF/C; 25 mm diameter).
The filters were washed once with 10 ml of the same ice-cold buffer and their radioactivity determined in the presence of 5 ml of Lumagel scintillation liquid in a Packard model 3033 liquid-scintillation spectrometer at a 36 % counting efficiency. All measurements were made in triplicate, and specific binding was defined as the total binding minus the non-specific binding, i.e. binding in the presence of 10-5 M-atropine. Calculations Measurements of residual atropine in the different tissue fragments by radio receptor assay Two cerebral cortices from saline-treated, atropinetreated and untreated ('naive') rats were homogenized in 15 ml of KRB-A and sonicated as described above. Samples were taken from the 'atropine' and 'saline' homogenates for [3H]QNB binding measurements.
After centrifugation at 64000 g for 30 min the supernatants from the 'atropine' and 'saline' samples were saved, all pellets were resuspended in 30 ml of KRB-A, and [3H]QNB binding to the membranes was carried out as described above.
The supernatants from atropine-and saline-treated samples were incubated at 100°C for 5 min to denature soluble proteins and subsequently centrifuged at 64000 g for 30 min. Pellets were discarded, and portions of the supernatants thus obtained were included in the binding incubations of membranes from naive untreated rats
Two displacement curves of [3H]QNB binding to membranes from untreated rats in the presence of 10 nMand 50 nM-atropine were also included to enable 'calibration' of the residual atropine concentration. The results of these experiments suggested that the residual atropine concentration in the tissue is 0.94 + 0.24 nM.
Measurements of the hydrolysis of phosphoinositides
The protocol outlined by Gonzales & Crews (1984) , with minor modifications, was followed.
(a) Brain-slice preparation. After dissection and removal of white matter, the cerebral cortices and hippocampi were placed in ice-cold Krebs-Ringer bicarbonate buffer (KRB-B; 118 mM-NaCI/4.7 mm-KC1/0.75 mM-CaCl2/ 1.18 mM-KH2PO4/ 1.1 mM-MgSO4/ 24.8 mM-NaHCO3/10 mM-glucose) previously equilibrated with 02/CO2 (19: 1).
Slices (thickness 400 ,um) of cerebral cortices or hippocampi were made in two perpendicular directions by using a Mcllwain tissue chopper (equipped with new razor blades for each experiment).
The minced tissue was dispersed in 6 vol. of KRB-B buffer and incubated for 30 min at 37°C under continuous bubbling with 02/CO2 in a shaking water bath. During this incubation period the buffer was changed five times.
(b) Incorporation of myo-l3Hlinositol into tissue slices of cerebral cortex and hippocampus. After the preincubation period of 30 min, slices were allowed to settle to the bottom of the Erlenmeyer flasks (50 ml) and the medium was replaced with prewarmed 02/CO2-bubbled KRB-B buffer containing myo-[3H]inositol (120-270 nM) (i.e. 1.5-3.4uCi/ml), and incubated at 37°C under constant 02/CO2 bubbling and agitation for 1 h in a shaking water bath. For measurements of the time-dependence of the incorporation of myo-[3H]inositol, 200 ,1 aliquots of slice suspensions were taken at various times and homogenized in 0.8 ml of ice-cold 0.63 mM-EGTA (0.5 mm final concn.) in a loose-fitting glass/Teflon homogenizer by five up-and-down strokes. Portions of the homogenate were taken for lipid extraction (as described below) and protein determination.
(c) Stimulation of the hydrolysis of inositol phosphates. The stimulation was performed in the presence of 8 mMLiCl substituted iso-osmotically for NaCl in the KRB-B buffer.
Tissue slices were rinsed twice with fresh KRB-B buffer subsequent to the myo-[3H]inositol incorporation (routinely 60 min) and resuspended in four times the tissue volume in KRB-B buffer. A 50 1dl portion of slice suspension was added to Beckman Biovials containing 175 u1 of KRB-B with LiCl (11.4mM) 10min before addition of the muscarinic, noradrenergic or serotonergic agonists or of KCI solution.
Stimulation ofphosphoinositide hydrolysis was started by the addition of 25 ,ul of buffer or drugs, the vials were bubbled with 02/CO2 (19:1), capped, incubated in a shaking water bath for 1 h or as otherwise specified. The incubation was stopped by the addition of 1 ml of chloroform/methanol (1:2, v/v).
The extraction of water-soluble products and separation of [3H]inositol phosphates from remaining [3H]inositol was performed exactly as described by Gonzales & Crews (1984) .
For further separation of the different [3H]inositol phosphates (inositol mono-, bis-and tris-phosphates), immediately after the extraction the water phases obtained were frozen on solid CO2 and stored at -70°C until use.
(d) Separation of I3Hjinositol phosphates. For separation of the different [3H]inositol phosphates, 2 ml of a 50 % (w/v) slurry of the anion-exchange resin AG 1-X8 (200-400 mesh; formate form; Bio-Rad) was poured into borosilicate columns (Bio-Rad) of 0.7 cm diameter, and the liquid allowed to drain. The samples were thawed on ice and diluted to 3 ml with double-distilled water and applied to the top of the resin, and the column was drained with no fluid left on the surface of the resin.
After draining the adsorbed myo-[3H]inositol and [3H]-inositol phosphates were eluted with 2 ml portions of the following solutions: (a) 5 mM-myo-inositol (8 ml); (b) 5 mM-Na2B407/60 mM-ammonium formate (10 ml); (c) 5 mM-Na2B407/150 mM-ammonium formate (18 ml); (d) 0.1 M-formic acid/0.4 M-ammonium formate (10 ml); (e) 0.1 M-formic acid/0.8 M-ammonium formate (10 ml); (J) 0.1 M-formic acid/ 1.2 M-ammonium formate (10 ml).
[3H]Inositol 1,4-bisphosphate and [3H]inositol 1,4,5-trisphosphate standards from Amersham International were eluted from the above columns in the 25th and 30th fraction respectively. The major peak of radioactivity was in the samples assumed to be myo-inositol phosphate.
Other peaks of radioactivity were not identified.
RESULTS
In agreement with previous reports, rats treated for 6-14 days with atropine (20 mg/kg subcutaneously) showed an increase in the number of [3H]QNB-binding sites in membranes from cerebral cortex and hippocampus as compared with membranes from control rats treated with phosphate-buffered saline ( Table 1 were determined by Scatchard plots and are shown as means +S.E.M. for determinations in separate treatment regimens. Significance: ***P < 0.0005; **P < 0.01; *P < 0.025 (Student's t test). was increased by 24+1 % (P < 0.0005) and 28+5 % (P < 0.005), respectively.
In the membranes from the hippocampus the binding affinity for [3H]QNB was lowered from 0.044+0.002 to 0.090 + 0.007 nm (P < 0.005) (mean + S.E.M.), and in membranes from the cerebral cortex from 0.067 + 0.004 nm to 0.085 + 0.004 nM (P < 0.001) (mean + S.E.M.), indicating there may be some residual atropine present in the tissue after the treatment (Table 1) .
We examined whether chronic atropine treatment, which could affect the binding of [3H]QNB (which binds to both MI and M2 muscarinic-receptor subtypes; Hammer et al., 1980) LiCl (8 mM) (Berridge et al., 1982) was studied in slices loaded with myo-[3H]inositol (120-270 nM) from cerebral cortex and from the hippocampus.
Carbachol (10-6-102 M) stimulated the release of [3H]inositol phosphates from 3H-prelabelled phosphoinositide pools with an EC50 value of approx. 23,CtM in both cerebral cortex (Fig. 2) and hippocampus (Fig. 3) .
In cerebral-cortical (Fig. 2) and hippocampal (Fig. 3) slices from atropine-treated rats the maximal release of [3H]inositol phosphates obtained during 1 h stimulation with carbachol (10-2 M) is not altered, but the concentration-dependence of this stimulation is shi-fted to the right, the EC50 values being 93 ltM for cerebral cortex (Fig. 2) and 126 /SM for hippocampus (Fig. 3) .
These shifts in concentration-dependence between the concentration-effect curves are not parallel; rather, the curve shapes are changed, suggesting that this effect cannot alone be explained by the presence of residual atropine in the tissue slices.
The maximal difference in phosphoinositide hydrolysis between atropine-and saline-treated rats was observed at 100 /tM-carbachol concentration. At this concentration a 26± I% (n = 4, P <0.0005) lower stimulation was observed in slices from cerebral cortex and 18±2 % (n = 2, P < 0.0005) lower stimulation in slices from hippocampus of atropine-treated animals than in corresponding tissue from saline-treated animals ( Fig. 4 ; Table 2 ).
This effect was even more clearly seen if the stimulation with the muscarinic agonist carbachol (100 /M) was carried out for 30 min rather than for 60 min ( Table 2) . The phosphoinositide breakdown in membranes from the cerebral cortex in atropine-treated rats was then 33 + 3 % lower than in samples from saline-treated rats (Table 2) . One possible explanation for the results obtained could be that the size of the labelled lipid pools available for muscarinic-receptor-mediated phosphoinositide breakdown and/or their capacity for incorporating myo-[3H]inositol ([3H]Ins) was diminished. Therefore the unstimulated time-dependent incorporation of myo-[3H]inositol into cerebral-cortical slices from atropinetreated and control rats was studied during a 3 h incubation period. No significant difference between tissues from atropine-treated and saline-treated rats was found during the first 1 h of myo-[3H]inositol incorporation (i.e. the time used in the stimulation experiments) (Fig. 5) . (In one of three experiments/treatments, though, a lower myo-[3H]inositol incorporation was measured in the cerebral-cortical slices of atropinetreated rats at incorporation times of 2 and 3 h.)
To check the eventual presence of heterologous desensitization we tested the ability of noradrenaline, phenylephrine and serotonin (5-hydroxytryptamine) to stimulate [3H]inositol phosphates release from cerebralcortical slices of atropine-and saline-treated rats at 100 4uM-agonist during a 30 min stimulation period (Table 3) .
Neither noradrenaline nor its oc2-receptor-specific analogue phenylephrine or serotonin showed any difference in their ability to atropine-treated rats at 5 mM-K' (Fig. 3) also remained unaltered at 12 mM-K+ concentration (Fig. 6 ). In an attempt to define which step(s) of the phosphoinositide hydrolysis cascade was (were) altered upon chronic treatment with atropine, we separated the different [3H]inositol phosphates from unstimulated and carbachol-stimulated cerebral-cortical slices by anionexchange chromatography as described by Berridge et al. (1982 Berridge et al. ( , 1983 and Downes et al. (1986) (Fig. 7a) . The first peak eluted was the remaining free myo-[3H]inositol eluted with solution a (5 mM-myo-inositol in distilled water; see the Experimental section). The peaks eluted with solution b (5 mM-Na2B4O7/60 mM-ammonium formate) were not identified, although one of them was probably glycerophosphoinositol (Berridge et al., 1983; Downes & Wusterman, 1983) . The main peak eluted in fraction no. 15 in Fig. 7 was assumed to be inositol 1-phosphate, and the peak eluted subsequently could be inositol 4-phosphate. The substance(s) eluted in fraction no. 25 had the same elution volume as the main [3H]inositol 1,4-bisphosphate 'standard' peak. The 3H-labelled substance(s) eluted in fractions 22-24 was not identified. The [3H]inositol 1,4,5-trisphosphate standard (Amersham International) was eluted at fraction no. 30 from these columns. The size of this peak in the samples varied greatly from one experiment to another. A separate peak for inositol 1,3,4,5-tetrakisphosphate was not found up to 1.2 M-ammonium formate (Batty et al., 1985; Downes et al., 1986; Hawkins et al., 1986) .
Clearly the difference in the elution profile of [3H]-inositol phosphates between the samples from salineand atropine-treated rats was found in the size/ amplitude of the inositol 1-phosphate peak (Fig. 7) ; a minor difference could also be measured, the following peak being probably inositol 4-phosphate (Fig. 7) , with no marked difference in the other peaks.
DISCUSSION
Muscarinic cholinergic responses can be rendered supersensitive by long-term blockade of the muscarinic receptors by antagonists (Herman & Slominska-Zurek, 1979) . This phenomenon has pharmacological implications, since most chronically administered psychoactive drugs such as the anti-psychotic phenothiazines and the tricyclic anti-depressants have high affinity 10`M) for muscarinic receptors in the brain (Snyder et 1985) and on the periphery and act there as antagonists (Rehavi et al., 1977) . There are several second-messenger systems activated by agonist occupancy of muscarinic receptors; these are: stimulation of cyclic GMP synthesis, inhibition of adenylate cyclase, stimulation of inositol phospholipid turnover, alteration of K+ conductance in certain neurons [cf. a recent review by Sokolovsky, (1984) ]. The only second-messenger response that has received careful biochemical study under conditions of subsensitivity or supersensitivity is the inhibitory coupling of the muscarinic receptor-agonist complex to the dopamine (3,4-dihydroxyphenethylamine)-sensitive adenylate cyclase system in the rat striatum (Olianas et al., 1984) .
The present study was aimed at an examination of another muscarinic-receptor-coupled response, namely the stimulation of release of [3H]inositol phosphates from myo-[3H]inositol-labelled phosphoinositides, which has been studied by several groups over the past 30 years (cf. Michell et al., 1981; Berridge et al., 1982; Hokin, 1985) .
The major findings of the study: (a) confirm that treatment with the muscarinic antagonist atropine leads to increases in muscarinic-receptor numbers in the cerebral cortex and hippocampus (Table I (Ariens et al., 1979; Stephenson, 1956) , which bind antagonists but are not coupled to any further response. Another possibility is that the newly synthesized receptors are not coupled to stimulation of the breakdown of inositol phospholipid, but to another second-messenger system, e.g. the adenylate cyclase system. Secondly, the rightwards shift in the concentration-response curves in Figs. 2 and 3 slices from atropine-and saline-treated rats (Fig. 5) No qualitative difference in the pattern of myo-[3H]inositol-labelled inositol phosphates released upon carbachol stimulation was found in samples from atropine-treated rats as compared with samples from saline-treated rats (Fig. 7) , although the amount of myo-[3H]inositol phosphate measured was significantly decreased in samples from atropine-treated rats. A possible explanation for the lack of observed difference in inositol 1,4-bisplhosphate and inositol 1,4,5-trisphosphate concentrations in atropine-treated and saline-treated samples may be that we have utilized too long an incubation time (60 min), since these phosphoinositides show the largest change in concentration with shorter (< 5 min) incubation with carbachol (Baird & Nahorski, 1986) . The absence of a change in the breakdown pattern of [3H]-phosphoinositides is not surprising, since adrenergic and serotonergic stimulation of phosphoinositide breakdown, which may involve the same cytosolic enzymes to produce mono-and di-phosphoinositol(s), was not affected by the atropine treatment (Table 3 ). The same argument may speak against the possibility that the activity of the enzyme myo-inositol 1-phosphatase or its affinity for Li' is altered upon atropine treatment.
As a possible explanation for our findings emerges an altered activity of a specific pool of phospholipase C which is associated with, or preferentially activated by, agonist-occupied muscarinic receptors.
